Duchenne-focused biotech Sarepta loses billions in value after trial fail
January 08, 2021 at 07:03 AM EST
Shares of Sarepta Therapeutics Inc., which employs more than 600 people in Massachusetts, were cut in half in after-hours trading Thursday night after the failure of a highly anticipated gene therapy for Duchenne muscular dystrophy.
